×
KALA BIO Total Liabilities 2016-2024 | KALA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
KALA BIO total liabilities from 2016 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
KALA BIO Total Liabilities 2016-2024 | KALA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
KALA BIO total liabilities from 2016 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.8B
Regeneron Pharmaceuticals (REGN)
$126.4B
Vertex Pharmaceuticals (VRTX)
$124.2B
Gilead Sciences (GILD)
$103.4B
Bristol Myers Squibb (BMY)
$100.3B
CSL (CSLLY)
$97.4B
GSK (GSK)
$88.2B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Argenex SE (ARGX)
$31.2B
BioNTech SE (BNTX)
$29.7B
Biogen (BIIB)
$28.9B
Moderna (MRNA)
$27.7B
Illumina (ILMN)
$20.7B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.4B
Vaxcyte (PCVX)
$13B
Incyte (INCY)
$12.8B
Insmed (INSM)
$12.6B
Exact Sciences (EXAS)
$12.6B
Sarepta Therapeutics (SRPT)
$12B
Bio-Techne Corp (TECH)
$11.9B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.5B
Intra-Cellular Therapies (ITCI)
$7.9B
Exelixis (EXEL)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B